About Shop TB-500.

What this site is

Shop TB-500 is a reading room for the peer-reviewed research on TB-500 and its parent protein, thymosin beta-4 — the literature gathered, read closely, and set out for anyone who wants the record rather than the pitch. It is a reading of that record, not a service that acts on it. No clinic stands behind it and no clinician answers; it renders no diagnosis, no treatment, and no medical advice. It makes nothing, stocks nothing, and sells nothing — what fills the room is citations, not product.

The name carries a "shop" word; the site deliberately does not. There is no catalog, no checkout, no price, and no vendor here. "Shop" is recast as the masthead of a reading room — a position relative to the literature, not a claim about services. The constructivist typesetting that runs through these pages is the argument made visible: the small seven-residue fragment set against the larger full-length protein, the diagonal that builds the vessel placed beside the diagonal that warns.

Why the fragment-versus-protein line runs through everything

TB-500's literature is a story of staged tensions, and we set them in type rather than averaging them away. The synthetic Ac-LKKTETQ heptapeptide that commerce calls TB-500 is not the same object as the full-length thymosin beta-4 protein where almost all the efficacy data live ^[5]. The pro-angiogenic mechanism that drives wound repair is the same activity that grounds the tumor/angiogenesis safety signal ^[5]. A wealth of animal and in-vitro findings sits beside the absence of any completed controlled human trial of the fragment ^[5]. We surface each of these on the page rather than burying them in even-weighted prose.

How we cite

Every quantitative claim on this site is attributed to a specific study in the study references and citations register — author, journal, year, and a resolvable link or identifier. Where a finding used full-length thymosin beta-4 rather than the seven-mer, we say so at the point of use. We do not recommend doses for humans, we describe what was administered to which species at which dose by which route. We name no products and no suppliers. The editorial framing in the domain name is a reading posture, not a service offering, and this page states that distinction explicitly.

What we are not

This is not a clinic, a pharmacy, a telehealth service, or a vendor, and nothing on this site is medical or legal advice. We do not evaluate anyone, prescribe anything, or help anyone obtain any substance. The regulatory reading on the TB-500 legal status and 503A access page is general information about the public regulatory landscape, drawn from FDA sources and stated in the present tense — it is not guidance on how to acquire TB-500, and it does not assert any future FDA decision as a certainty. Where the literature is thin or absent — which, for the seven-mer in humans, is most of the time — we say so rather than fill the gap with confident prose. That honesty is the whole point of the project: a reader should leave knowing exactly what the published record does and does not establish about TB-500 and thymosin beta-4.